Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
SUVEN LIFE SCIENCES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUVEN LIFE SCIENCES Mar-23 |
ADCOCK INGRAM Jun-14 |
SUVEN LIFE SCIENCES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 94 | 315 | - | |
Low | Rs | 45 | 228 | - | |
Sales per share (Unadj.) | Rs | 0.6 | 93.8 | - | |
Earnings per share (Unadj.) | Rs | -5.4 | -23.6 | - | |
Cash flow per share (Unadj.) | Rs | -5.1 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 17.2 | 73.6 | - | |
Shares outstanding (eoy) | m | 218.07 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 111.8 | 2.9 | 3,862.5% | |
Avg P/E ratio | x | -12.8 | -11.5 | 111.4% | |
P/CF ratio (eoy) | x | -13.5 | -13.9 | 97.7% | |
Price / Book Value ratio | x | 4.0 | 3.7 | 109.4% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 15,131 | 45,814 | 33.0% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 186 | 2,875 | 6.5% | |
Avg. sales/employee | Rs Th | 0 | 3,688.3 | - | |
Avg. wages/employee | Rs Th | 0 | 669.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -929.4 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 135 | 15,834 | 0.9% | |
Other income | Rs m | 84 | 111 | 76.2% | |
Total revenues | Rs m | 220 | 15,945 | 1.4% | |
Gross profit | Rs m | -1,196 | -2,744 | 43.6% | |
Depreciation | Rs m | 65 | 683 | 9.6% | |
Interest | Rs m | 5 | 429 | 1.3% | |
Profit before tax | Rs m | -1,183 | -3,745 | 31.6% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 234 | 0.0% | |
Profit after tax | Rs m | -1,183 | -3,990 | 29.6% | |
Gross profit margin | % | -883.6 | -17.3 | 5,099.1% | |
Effective tax rate | % | 0 | -6.2 | 0.0% | |
Net profit margin | % | -873.5 | -25.2 | 3,466.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,455 | 11,597 | 29.8% | |
Current liabilities | Rs m | 1,050 | 6,525 | 16.1% | |
Net working cap to sales | % | 1,776.0 | 32.0 | 5,544.4% | |
Current ratio | x | 3.3 | 1.8 | 185.1% | |
Inventory Days | Days | 3,948 | 111 | 3,560.0% | |
Debtors Days | Days | 218 | 124 | 175.6% | |
Net fixed assets | Rs m | 1,373 | 6,760 | 20.3% | |
Share capital | Rs m | 218 | 74 | 296.6% | |
Net worth | Rs m | 3,753 | 12,428 | 30.2% | |
Long term debt | Rs m | 0 | 4,367 | 0.0% | |
Total assets | Rs m | 4,828 | 23,477 | 20.6% | |
Interest coverage | x | -218.8 | -7.7 | 2,830.1% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0 | 0.7 | 4.2% | |
Return on assets | % | -24.4 | -15.2 | 160.8% | |
Return on equity | % | -31.5 | -32.1 | 98.2% | |
Return on capital | % | -31.4 | -19.8 | 158.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -1,031 | 1,352 | -76.3% | |
From Investments | Rs m | -2,606 | -415 | 628.1% | |
From Financial Activity | Rs m | 3,955 | 3,964 | 99.8% | |
Net Cashflow | Rs m | 317 | 4,900 | 6.5% |
Compare SUVEN LIFE SCIENCES With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare SUVEN LIFE SCIENCES With: ZENITH HEALTH SANDU PHARMA OMKAR PHARMACHEM TTK HEALTHCARE AURO LAB.
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.